Latest Breaking News On - Medicine stock down - Page 1 : vimarsana.com

Insider Selling: Editas Medicine, Inc (NASDAQ:EDIT) CEO Sells 12,191 Shares of Stock

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) CEO Gilmore Neil O’neill sold 12,191 shares of the company’s stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $5.50, for a total value of $67,050.50. Following the sale, the chief executive officer now owns 315,279 shares of the […]

Gilmore neil oneillEntrypoint capitalHeadlands technologiesJpmorgan chase coRussell investments group ltdEditas medicine incEditas medicineGet free reportNeilo neillMedicine stock downStreet marketsInvestments groupLeber congenital amaurosisEditas medicine daily

Disc Medicine (NASDAQ:IRON) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Disc Medicine (NASDAQ:IRON – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $85.00 price objective on the stock. Several other equities research analysts also recently commented on the company. Morgan Stanley reduced their target price on Disc […]

United statesRaymond jamesStifel nicolausWilliam richard whiteCharles schwab investment management incMorgan stanleyDisc medicine company profileYork mellon corpBarclays plcDisc medicine incCantor fitzgeraldSwiss national bankVictory capital management incDisc medicineFree reportModerate buy

Editas Medicine (NASDAQ:EDIT) Cut to Sell at StockNews com

Editas Medicine (NASDAQ:EDIT) Cut to Sell at StockNews com
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Los angelesUnited statesGilmore neil oneillBaisong meiInternational assets investment managementVanguard group incDimensional fund advisorsMorgan stanleyEditas medicine incJpmorgan chase coCharles schwab investment management incLos angeles capital managementEditas medicineFree reportMedicine stock downGet free report

Citigroup Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $15 00

Citigroup Lowers Editas Medicine (NASDAQ:EDIT) Price Target to $15 00
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Baisong meiGilmore neil oneillEditas medicine company profileDimensional fund advisorsVanguard group incCharles schwab investment management incYork mellon corpMorgan stanleyJpmorgan chase coEditas medicine incMirae asset global investments coEditas medicineFree reportMedicine stock downGet free reportNeilo neill

Prime Medicine, Inc (NYSE:PRME) Receives Average Rating of Moderate Buy from Analysts

Prime Medicine, Inc (NYSE:PRME) Receives Average Rating of Moderate Buy from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Stifel nicolausRobert nelsenSg americas securitiesOppenheimer coChelsea counsel coMirae asset global investments coMedicine incMedicine company profileGreen alpha advisorsPrime medicineGet free reportMedicine stock downDirector robert nelsenAsset global investmentsAlpha advisorsGet free